4 hours ago
1
Grandbrothers/iStock Editorial via Getty Images
Johnson & Johnson (NYSE:JNJ) announced on Thursday that the U.S. FDA granted priority review for its new drug application aimed at getting marketing approval for TAR-200, a drug-releasing system for patients with a certain form of bladder cancer.
TAR-200 is
English (US) ·